Resultados de la búsqueda 1661-1670 of 11084 for prostate cancer

  1. Neurología - Ensayos clínicos

    ... cancer, (2-4) advanced, unresectable breast cancer (up to 6 donors per phenotype: triple negative [HER2, estrogen and progesterone receptor (ER and PR) all ...

  2. Neurología - Ensayos clínicos

    Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 donors with colorectal cancer who have no clinical evidence of ...

  3. Neurología - Ensayos clínicos

    ... cancer, (2-4) advanced, unresectable breast cancer (up to 6 donors per phenotype: triple negative [HER2, estrogen and progesterone receptor (ER and PR) all ...

  4. Neurología - Ensayos clínicos

    ... cancer, (2-4) advanced, unresectable breast cancer (up to 6 donors per phenotype: triple negative [HER2, estrogen and progesterone receptor (ER and PR) all ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... cancer therapy (single or multiple) and stem cell transplant. A Study of Endometrial Cancer Testing With Vaginal and Endometrial Cell Samples. Rochester ...

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 donors with colorectal cancer who have no clinical evidence of ...

  7. Neurología - Ensayos clínicos

    Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 donors with colorectal cancer who have no clinical evidence of ...

  8. Neurología - Ensayos clínicos

    Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 donors with colorectal cancer who have no clinical evidence of ...

  9. Neurología - Ensayos clínicos

    A Blood Collection Protocol to Study the Immune Responses of Cancer Patients with Malignancies. Rochester, Minn., Scottsdale/Phoenix, Ariz. This is a peripheral ...

  10. 5 cosas que debe saber sobre el cáncer de páncreas - Red de noticias de Mayo Clinic

    El Día Mundial contra el Cáncer es el 4 de febrero. «Este no es un tipo de cáncer particularmente común, pues el riesgo que cualquier paciente sin ningún ...